All News
ACR/EULAR Classification Criteria for IgG4 Related Disease
IgG4-related disease (IgG4-RD) is a relatively new disorder since 2003, and may present as a diagnostic challenge as it can cause fibroinflammatory pathology in nearly any organ.
Read ArticleRheumNow Podcast –Favorites of ACR 2019 (11.22.19)
Dr. Jack Cush recaps standout presentations and information from ACR 2019 held in Atlanta November 9-12, 2019.
Read ArticleSjogren's Syndrome at Risk for Psychiatric Disorders
A population-based claims study from Taiwan shows significantly increased incidences of depressive disorder, anxiety disorder, and sleep disorder in patients with primary Sjögren’s syndrome (pSS).
Read ArticleRheumNow Podcast – EULAR 2019 Streamin' - (6.14.19)
Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. Dr. Jack Cush reports from Madrid on several novel presentations from EULAR 2019, including low-dose steroids in hand OA, ABA vs. ADA in double positive RA patients, psoriasis predictors of PsA, tildrakizumab and more.
Read ArticleEULAR 2019 - Day 1 Report
Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. Here are a few of the highlights from day 1 EULAR in Madrid, including another IL-23 inhibitor, BTK inhibition, abatacept in Sjogren's syndrome, don't repeat the ANA, and drug free remission in systemic JIA.
Sjögren's Syndrome Differs in Minorities
Minority groups in the U.S. have differing rates of Sjögren's syndrome and exhibit distinct clinical patterns of the disease, a large cross-sectional study revealed.
The percentage of American Indians in a SS cohort of 610 patients was much higher than expected, at 25.3%, whereas the percentage of African Americans was lower, at 3.1%. In addition, American Indians had higher levels of disease activity and more extraglandular manifestations, whereas African Americans had a symptom pattern associated with subsequent lymphoma development, researchers reported in Arthritis Care & Research.
RheumNow Podcast – EULAR 2019 Streamin' - (6.14.19)
Dr. Jack Cush reports from Madrid on several novel presentations from EULAR 2019.
1. Genovese Vagal nerve stimulator in RA
Read ArticleEthnicity Matters in Sjogren's Syndrome
Among the ethnically diverse residents of Manhattan, certain groups had markedly different incidence rates of primary Sjogren's syndrome, a retrospective study found.
Read ArticleThe ACR17 RheumNow Week in Review - 1 December 2017
Dr Jack Cush reviews nighlights and news from the past 2 weeks on RheumNow.com. This week's report includes new drug approvals, disappointing ACR guidelines, Lyme & Zika, infertility, dermatomyositis skin outcomes and myositis-associated cancer testing.
Read ArticleACR 2017 - Day 2 Highlights
In the afternoon on Monday, the ACR ran a clinical symposium on gout. One presentation stood out, on “Asymptomatic hyperuricemia” (AH) by M. Pillinger, MD from NYU Medical School. At issue is when should AH be treated.
Read ArticleThe RheumNow Week in Review - 6 October 2017
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr. Jack Cush discusses when to hold the biologic, lymphoma risk with tofacitinib, early clues to the diagnosis of RA, biologic use in pregnancy, what's killing psoriasis patients and the 2016 top 5, best selling drugs in rheumatology.
Read ArticlePrimary Sjögren's Syndrome Guideline from the British Society for Rheumatology
The British Society of Rheumatology (BSR) has been accredited by NICE to develop a guidance document for the management of primary Sjögren's Syndrome intended for rheumatologists, general physicians, general practitioners, specialist nurses and other specialists (e.g.
Read ArticleThe RheumNow Week in Review – 24 March 2017
Dr. Jack Cush reviews news and highlights from the past week on RheumNow.com.
Read ArticleSjogren's Syndrome Foundation's 2017 Sjogren's Treatment Guidelines
Dr. Steven Carsons and an expert committee of the Sjogren's Syndrome Foundation have published a clinical practice guidelines (CPGs) and recommendations for the managment of Sjögren's syndrome.
Read ArticleThe RheumNow Week in Review – 6 January 2017
Dr. Jack Cush reviews highlights from the first week of 2017 on RheumNow.com.
Happy New Year!
Read ArticleBiopsy Proven Renal Involvement in Sjogren's Syndrome
A French multicenter study of primary Sjogren's syndrome (pSS) patients fulfilling the American–European Consensus Group criteria or enlarged American–European Consensus Group criteria were retrospectively studied based on having biopsy-proven renal involvement.
Read ArticleLong-Term Outcomes of Aromatase Inhibitor Arthralgias
Aromatase inhibitors (AI) are often given in the setting of estrogen receptor-positive (ER+) breast cancer therapy.
Read ArticleRheumNow Week in Review – 15 July 2016
Dr. Jack Cush reviews highlights from this week's rheumatology news on RheumNow.com.
Read Article
FDA Approves Xiidra (Lifitegrast) for Dry Eyes
MedScape has reported that the US Food and Drug Administration (FDA) has approved lifitegrast ophthalmic solution (Xiidra, Shire) for the treatment of signs and symptoms of dry eye disease.
Read Article